UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2), p.573-582

2009

Volltextzugriff (PDF)

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Investigational new drugs, 2021-02, Vol.39 (1), p.163-174

2021

Volltextzugriff (PDF)

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

Journal of palliative medicine, 2013-06, Vol.16 (6), p.623-631

2013

Volltextzugriff (PDF)

The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis

Molecular therapy, 2000-02, Vol.1 (2), p.130-144

2000

Volltextzugriff (PDF)

Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Blood, 2021-11, Vol.138 (Supplement 1), p.1337-1337

2021

Volltextzugriff (PDF)

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2024-01, Vol.42 (3), p.324-335

2024

Volltextzugriff (PDF)

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Nature (London), 2024-03, Vol.627 (8004), p.646-655

2024

Volltextzugriff (PDF)

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

Cancer chemotherapy and pharmacology, 2021-12, Vol.88 (6), p.921-930

2021

Volltextzugriff (PDF)

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2022-06, Vol.40 (17_suppl), p.LBA8507-LBA8507

2022

Volltextzugriff (PDF)

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

Investigational new drugs, 2020-06, Vol.38 (3), p.844-854

2020

Volltextzugriff (PDF)

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9503-9503

2020

Volltextzugriff (PDF)

p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin

International journal of oncology, 1999-01, Vol.14 (1), p.5

1999

Volltextzugriff (PDF)

Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.5712-5712

2023

Volltextzugriff (PDF)

JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS4147-TPS4147

2014

Volltextzugriff (PDF)

p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ

Experimental cell research, 2001-01, Vol.262 (2), p.154-169

2001

Volltextzugriff (PDF)

1 – 25 von 570

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(416)
Mit Volltextzugriff
(517)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(332)
Life Sciences & Biomedicine
(180)
Humans
(144)
Technology
(114)
Computer Science
(90)
Computer Science, Theory & Methods
(70)
Male
(63)
Animals
(61)
Female
(61)
Computer Science, Artificial Intelligence
(56)
Physical Sciences
(42)
Middle Aged
(41)
Biological And Medical Sciences
(33)
Mice
(33)
Aged
(32)
Medical Sciences
(31)
Adult
(30)
Science & Technology - Other Topics
(28)
Oncology
(27)
Engineering
(25)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(183)
Ingenta
(178)
MEDLINE
(176)
Ebook Central Perpetual and DDA
(165)
eBooks on EBSCOhost
(164)
Ovid database
(113)
Elsevier ScienceDirect Journals Complete
(86)
Publisher or Other Site
(83)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(57)
IngentaConnect Journals
(57)
Wiley Online Library All Journals
(51)
Wiley Online Library
(39)
SpringerLink Series
(27)
Springer Journals
(23)
Nature
(21)
IEEE/IET Electronic Library (IEL)
(18)
SAGE Journals Online
(16)
Nexis Uni
(12)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(11)
Oxford Journals
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors

γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

The TRAIL Decoy Receptor TRUNDD (DcR2, TRAIL-R4) Is Induced by Adenovirus-p53 Overexpression and Can Delay TRAIL-, p53-, and KILLER/DR5-Dependent Colon Cancer Apoptosis

Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)

p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade

JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma

p53-Independent Upregulation of KILLER/DR5 TRAIL Receptor Expression by Glucocorticoids and Interferon-γ

Suchergebnisse filtern